



13th February 2026

SomnoMed 1H FY26 Results Webinar and Investor Presentation

SomnoMed Limited (ASX “SOM” or the Company) advises its 1H FY26 Financial Results and Investor Presentation will be released to the ASX pre-market open on Friday 27th February 2026.

Karen Borg and Amrita Blickstead, Co-CEOs, and Ye-Fei Guo, CFO, will host an investor presentation and Q&A on the 1H FY26 Results via a webinar commencing at 10am AEDT on Friday 27 February 2026.

Participants are invited to register for the webinar via the following link:

https://us06web.zoom.us/webinar/register/WN_uZTfqJmmSFKwOUSqj0L9lQ

Once you have registered you will receive an email confirming your attendance and information about joining the webinar.

Alternatively, participants may dial into the webcast for audio only:

Australian dial in numbers: +61 3 7018 2005 or +61 7 3185 3730 or +61 8 6119 3900 or +61 8 7150 1149 or +61 2 8015 6011

Meeting ID: 872 4858 6864

Passcode: 465126

Dial in numbers for other countries:

<https://us06web.zoom.us/join?m=ODcyNDg1ODY4NjQ.9zg51DykvRNDZCnFXtRNPuTMMtoiaX6>

Authorised by the Company Secretary of SomnoMed Limited

For further information please contact

Investor Relations: ir@somnomed.com

SomnoMed Limited - 20 Clarke St, Crows Nest, NSW, Australia 2065

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 1 million patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>